Tom Spurgeon, Contributing Writer03.06.13
Several companies working in Oral Solid Dosage (OSD) outsourcing enjoyed a solid-to-spectacular 2012. Successful CMOs reached by Contract Pharma cited building on several years of focused attention to specific technologies, personnel issues, existing relationships and sound capacity management in realizing dramatic gains in the area. An optimistic forecast by several key players suggests opportunities should continue to present themselves as pharma companies of all sizes aggressively and more wholly engage focused outsourcing strategies.
Michael Valazza, vice president, Global Business Development — Oral Solids and Controlled Release Technologies at Catalent Pharma Solutions, told us that his company has continued to see significant increases in demand for their services in this area. To that end, Catalent has just announced a major expansion to one of its manufacturing sites for oral solids, as Mr. Valazza cited, “We’re in the final design of a major expansion of our largest facility for caplets and capsules. That expansion will break ground in April and be done by October 2014. This major expansion in that facility is in direct response to the
Michael Valazza, vice president, Global Business Development — Oral Solids and Controlled Release Technologies at Catalent Pharma Solutions, told us that his company has continued to see significant increases in demand for their services in this area. To that end, Catalent has just announced a major expansion to one of its manufacturing sites for oral solids, as Mr. Valazza cited, “We’re in the final design of a major expansion of our largest facility for caplets and capsules. That expansion will break ground in April and be done by October 2014. This major expansion in that facility is in direct response to the
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
